In the JAVELIN tumour-agnostic study, which evaluated the combination of anti-PD-L1 avelumab and PARPi talazoparib in patients with BRCA1/2 or ATM pathogenic alterations, ORR was 26.4%, thereby not meeting the prespecified target ORR of 40% [290, 291]. The gene discussed is BRCA1; the disease is neoplasm.